The SCCS (Scientific Committee on Consumer Safety) adopted SCCS/1629/21 Opinion on Platinum (nano), Colloidal Platinum (nano) and Acetyl tetrapeptide-17 Colloidal Platinum (nano) at its plenary meeting on 24-25 June 2021.
Primary name and/or INCI name:
- P1: Aqua, Platinum
- P2: Aqua and Platinum
- P3: Colloidal Platinum
- P4: Platinum, acetyl-L-cystein-S-yl-L-lysinyL-L-phenylalaninyl-L-arginine; Acetyl tetrapeptide-17 (and) Colloidal platinum
- Metallic nanoparticle platinum
- Colloidal platinum
- Acetyl tetrapeptide-17 (and) Colloidal platinum
Having considered all the information provided by the Notifiers, and that obtained from other sources, the SCCS is of the opinion that it is not possible to carry out a safety assessment of any of the notified platinum nanomaterials due to limited or missing essential information. The limited amount of data provided by the Notifiers also does not correspond to the requirements and data standards as indicated in the SCCS Guidance (SCCS 1611/19), and the SCCS Memorandum (SCCS/1524/13).
To enable safety assessment by the SCCS, the Notifiers need to provide the necessary information, a summary of which is provided in Annex I.
In the absence of sufficient data to allow safety assessment, the SCCS has considered the different aspects of platinum nanomaterials that could raise a concern over consumer safety.
As detailed in Annex II, the SCCS has concluded that there is a basis for concern that the use of platinum, colloidal platinum, and acetyl tetrapeptide-17 colloidal platinum (nano) in cosmetic products can pose a risk to the consumer. The SCCS will be ready to assess any evidence provided to support safe use of the materials in cosmetic products.
SCCS / 1630/21 Final Opinion can be consulted here.